Every breakthrough in cancer treatment started with a question in a laboratory.
From chemotherapy to immunotherapy and targeted therapies, research continues to transform cancer care and improve survival worldwide.
Science today saves lives tomorrow.
#CancerResearch#Oncology
🚨 Prostate cancer is one of the most commonly diagnosed cancers in men worldwide.
Early-stage disease often causes no symptoms, making regular screening and awareness critically important.
Early detection can save lives.
🔬 Research 🎗 Awareness ❤️ Prevention
#ProstateCancer
Notevery substance is toxic The dose determines the poison
A compound can be life saving at one dose and harmful at another
This fundamental principle of toxicology continues to guide modern drug development and safety assessment Toxicology Drug Safety Science Matters
#Toxicology
@Bsp4u अगर सरकार बड़े उद्योगों को भूमि, वित्तीय सहायता और नीतिगत सहयोग दे सकती है, तो कैंसर दवाओं के उत्पादन के लिए भी इच्छुक नवाचारकर्ताओं को समान अवसर मिले
मुझे भी उचित फंडिंग, भूमि और आवश्यक अनुमतियाँ दी जाएँ तो मैं कैंसर के लिए दवाओं के उत्पादन की दिशा में काम करने को तैयार हूँ।
Over 40% of cancers may be preventable through lifestyle modifications, early screening, and reducing exposure to known carcinogens.
Prevention remains one of the most powerful weapons against cancer.
🔬 Research 📚 Awareness ❤️ Early Detection
#Cancer#Oncology#CancerResearch
This is pioneer research from LMIC in which effectiveness of pre-emptive TMR in acutely injured patients to mitigate the primary cause of post amputation pain (PAP) was assessed.
https://t.co/SdTh4gJOoU
जो #media , #UGC वाले मुद्दे पर आंखो पर पट्टी बांध कर रखा था आज CJP , CJP कर रही हैं, अगर पार्टी संस्थापक हिन्दु सवर्ण होते तो अब तक देशद्रोह का मुकदमा दर्ज कर गिरफ्तार कर लिया जाता #cjp_पार्टी
#ASCO26 GU Oncology Spotlight 🚨
🔬 Abstract 4515 | GemFLP in advanced urinary tract adenocarcinoma
Phase II study of frontline gemcitabine + 5-FU/leucovorin + cisplatin in advanced urachal and non-urachal urinary tract adenocarcinoma
Superb presentation by Emanuele Crupi, MD
@emanuele_crupi@ASCO@OncoAlert
🔵 Why this matters
Urinary tract adenocarcinomas are rare.
Prospective data are limited, treatment standards are not well defined, and most decisions are extrapolated from small series, institutional experience, or adjacent disease models.
So even a single-arm prospective dataset can be highly useful.
🟦 Study design
• Phase II, single-arm, single-center study
• N = 46
• Urachal adenocarcinoma: 28 pts
• Non-urachal adenocarcinoma: 18 pts
• Frontline GemFLP given q21 days until progression or unacceptable toxicity
Primary endpoints:
➡️ ORR
➡️ OS
🟩 Key efficacy signal
GemFLP showed clinically meaningful activity:
• ORR: 43.5% overall
• ORR: 35.7% in urachal adenocarcinoma
• ORR: 55.6% in non-urachal adenocarcinoma
• Median PFS: 4.6 months
• Median OS: ~21 months
For a rare disease with limited prospective benchmarks, this is useful.
🟨 Biomarker signal
Baseline CA125 was associated with worse OS.
Important caveat:
This was exploratory and needs validation in larger independent cohorts.
Still, it is a potentially interesting signal for risk stratification in a disease where biomarkers are sparse.
🟧 Safety
GemFLP was described as manageable.
Main toxicities included:
• anemia
• dehydration
• thrombocytopenia
• neutropenia
No grade 5 events were reported.
🔴 Important caveats
This is not a definitive standard-setting randomized trial.
Limitations matter:
• single-arm design
• small sample size
• single-center experience
• rare-disease heterogeneity
• exploratory biomarker analysis
• subgroup comparisons are imprecise
🧠 My take
In rare GU tumors, the value of a study is not always measured only by whether it changes guidelines immediately.
Sometimes the value is that it gives the field a prospective reference point.
GemFLP may represent a reasonable current option for carefully selected patients with advanced urachal or non-urachal urinary tract adenocarcinoma — and a benchmark for future studies.
Rare tumors need prospective data.
This is exactly why studies like this matter.
#ASCO26 #GUOnc #BladderCancer #UrothelialCancer #UrachalCancer #RareTumors #ClinicalTrials #PrecisionOncology
@emanuele_crupi@PGrivasMDPhD@MattGalsky@shilpaonc@urologysummit@OpenMedInsights@OncLive@TargetedOnc@CancerNetwrk@ASCOPost@ecancer@VJOncology@curetoday@NEJM@JCO_ASCO
@Megatron_ron VAXIRA® isn't new. It's a therapeutic lung cancer vaccine that has been around for years and was approved in Cuba and Argentina long ago. Important research, but not a recent breakthrough.
The National Pharmaceutical Pricing Authority has fixed the retail price of 30 drug formulations, including Vitamin D3 Oral Solution, Calcium, Vitamin D3, Methylcobalamin, L-Methylfolate Calcium, Pyridoxal-5 phosphate and others.
@aajtak@himanshdxt@sharatjpr oxytocin cannot cause death would be as inaccurate as saying it definitely did. Like any potent drug, misuse, overdose, or improper administration of oxytocin can lead to severe complications. The cause must be established through scientific toxicological and forensic evidence
A 12y girl was allegedly trafficked abused and abandoned How did multiple systems fail to protect a child? What steps are being taken to prevent such crimes and ensure swift justice for the victim? Accountability and action are needed #ChildSafety#JusticeForHer@UNHumanRights
A 12-year-old Bihar girl allegedly sold by her mother “for Rs 16,000 and 10 saris” to a 40-year-old man from #Chandauli in neighbouring #UttarPradesh was repeatedly raped by him after a sham temple marriage, only to be abandoned and preyed on by an auto driver in #Varanasi before being rescued.
More details 🔗https://t.co/YJpFqJEHwP
@AshokShrivasta6@vineetJindal19 Sir, a basic Google search would show that South Asia has several countries. Questioning the government doesn't make someone Pakistani or a terrorist. Facts should come before allegations.
@TheOfficialSBI ATM card block hai, new card ke liye online apply nahi ho raha. Net Banking password bhi bhool gaya hoon aur home branch door hai. Branch visit bina solution possible hai? Please guide. #SBI